



Guideline 14.3 - Acute Coronary Syndromes: Reperfusion Strategy

Summary

To whom does this guideline apply?

This guideline applies to adults.

Who is the audience for this guideline?

This guideline is for use by first responders and health professionals.

Summary of Recommendations

The Australian and New Zealand Committee on Resuscitation (ANZCOR) makes the following recommendations:

- 1. Timely diagnosis of ST-elevation myocardial infarction (STEMI) within <u>10 minutes</u> of first medical contact using 12-lead electrocardiogram (ECG) is essential [Good Practice Statement].
- 2. ANZCOR recommends early reperfusion through a defined system of care with either percutaneous coronary intervention (PCI) or fibrinolytic therapy [Good Practice Statement].
- 3. ANZCOR suggests primary PCI (PPCI) is the preferred strategy and should be performed within <u>120 minutes</u> of first medical contact [Good Practice Statement].
- 4. ANZCOR suggests if PPCI cannot be achieved within 120 minutes a strategy of fibrinolysis followed by immediate transfer to a PCI centre is recommended [CoSTR 2015, weak recommendation, very-low-quality evidence].
- 5. ANZCOR suggests after successful fibrinolysis, routine angiography within 2 to 24 hours is advised [CoSTR 2015, weak recommendation, very-low-quality evidence].
- 6. ANZCOR recommends immediate angiography and if indicated PCI, for STEMI patients with return of spontaneous circulation (ROSC) after cardiac arrest [CoSTR 2015, strong recommendation, low quality evidence CoSTR 2022 no change].
- 7. Urgent angiography in non ST-elevation myocardial infarction (NSTEMI) should be considered in patients with refractory chest pain, haemodynamic instability, evidence of hypoperfusion, life-threatening arrhythmia, heart failure, or high-risk ECG changes [Good Practice Statement].

1.0 | Introduction

ST-elevation myocardial infarction (STEMI) usually occurs due to the acute thrombotic occlusion of a major epicardial artery, secondary to the disruption/rupture of an atherosclerotic plaque. Early reperfusion minimises myocardial necrosis and mortality. Restoring coronary blood flow and myocardial reperfusion either by PCI or fibrinolytic therapy has been demonstrated to improve outcomes in patients presenting within 12 hours of symptom onset and is recommended. Page 12.3

The development of clearly defined hospital STEMI networks and non-PCI centre bypass reduces treatment delays and improves times to reperfusion. There is a growing body of observational data suggesting out-of-hospital cardiac arrest (OHCA) patients should be considered for transport to a specialist cardiac arrest centre with primary percutaneous coronary intervention (PPCI) capacity as part of wider regional system of care for the management of patients with OHCA. There is a growing body of observational data suggesting out-of-hospital cardiac arrest (OHCA) patients should be considered for transport to a specialist cardiac arrest centre with primary percutaneous coronary intervention (PPCI) capacity as part of wider regional system of care for the

2.0 | Reperfusion Strategies

2.1 | Diagnosis of STEMI

The target time for diagnosis of STEMI is within 10 minutes of first medical contact, either in the Emergency Department (ED) or with an ambulance crew obtained 12-lead ECG performed in the pre-hospital environment. After a STEMI is confirmed the patient is sent for PPCI in the cardiac centre, urgently transferred to a cardiac centre for PPCI, or given thrombolysis.

2.2 | Primary Percutaneous Coronary Intervention (PPCI)

PPCI is the preferred reperfusion strategy with the best outcomes demonstrated in a number of large meta-analyses provided it is performed in a timely manner by an experienced team.^{1, 15, 16, 17, 18, 19} If delay to treatment is similar the benefit is mostly driven by decreased mortality, reduced rates of recurrent myocardial infarction and of intracranial haemorrhage (ICH) in the PPCI treated patients compared to those receiving fibrinolysis. PPCI should be undertaken within 120 minutes of first medical contact, and if this time frame is not achievable at the receiving centre, or by transfer to an appropriate PCI centre then suitable patients should receive thrombolysis.

2.2 | Primary PCI Strategy

Patient delays to first medical contact occur and PPCI will be effective up to 12 hours from symptom onset. PPCI may also be appropriate beyond 12 hours from symptom onset in the presence of hemodynamic instability, arrhythmias, or ongoing symptoms of ischaemia.¹

To achieve the 120 minute reperfusion goal, target times from first medical contact to reperfusion (in PPCI defined as wire crossing the lesion/occlusion) is < 90 minutes for patients diagnosed elsewhere and then transported by ambulance to a PCI centre. A goal of < 60 minutes is set for patients presenting directly to a PCI centre.¹

Access to PPCI may be limited in large parts of Australia and New Zealand and there are several strategies that can be undertaken to reduce the time delay to PPCI. These include developing hospital STEMI networks with clear reperfusion management pathways; pre-hospital 12-lead ECGs to facilitate earlier diagnosis; advanced notification of the results of the 12-lead ECG at the receiving institute for rapid reperfusion on arrival of the STEMI patient; availability of pre-hospital fibrinolysis; the bypassing of non-PCI centres when appropriate (if PPCI available within 120 minutes); and the bypassing of the emergency department in PCI centres.^{4, 5, 6, 7, 8, 9, 10} In a fully integrated STEMI system of care, all patients diagnosed with STEMI in the pre hospital system should be transported to PPCI capable centre [CoSTR 2015, weak recommendation, low-quality evidence]. ANZCOR suggests a strategy of fibrinolysis followed by immediate transfer to a PCI centre if PPCI cannot be achieved within 120 minutes [CoSTR 2015, weak recommendation, moderate certainty evidence]. If fibrinolysis is successful a pharmaco-invasive strategy (defined as angiography within 2 to 24 hours after fibrinolysis) is preferred.

2.3 | Percutaneous Coronary Intervention (PCI) in cardiac arrest patients with Return of Spontaneous Circulation (ROSC)

ANZCOR recommends performing immediate angiography and if necessary, PCI, in patients with ST-elevation or STEMI equivalent changes (Refer to ANZCOR Guideline 14.1) on the standard 12-lead ECG who respond to cardio-pulmonary resuscitation with ROSC [CoSTR 2015, strong recommendation, low quality evidence. CoSTR 2022 no additional randomised data]. Post arrest coma is common and should not be a contraindication to angiography and PCI. Evolving evidence has demonstrated a role for extracorporeal membrane oxygenation (ECMO) to facilitate revascularisation among patients without ROSC.¹ In patients without ST elevation on ECG following cardiac arrest, and no features of shock or requirement of inotropic support for haemodynamic instability, recent randomized trials have demonstrated no benefit with early angiography ^{20, 21} Therefore, these patients can be managed medically initially, with non-urgent angiography as indicated, later during the admission once stabilised. An early or a delayed approach to angiography is reasonable [CoSTR 2022, weak recommendation, low-certainty evidence]. Several complex clinical factors may influence the decision to proceed to angiography and intervention. These include patient age, the presenting rhythm, whether the arrest was witnessed, the requirement for haemodynamic support and the known presence of

co-morbidities such diabetes mellitus, renal failure, and chronic heart failure. In inpatients with evidence of shock or need for inotropic support post cardiac arrest we support urgent PCI. Decisions around optimal timing of PCI need to be made around other evidence-based strategies in post arrest care, e.g. temperature control (Refer to ANZCOR Guideline 11.8).

2.4 | Fibrinolytic Therapy

 Fibrinolytic therapy is indicated among patients with STEMI, (including posterior) or clear new Left Bundle Branch Block. If PPCI is not available within 120 minutes of first medical contact then fibrinolysis should be considered, this can be administered up to 12 hours from symptom onset. Tenecteplase is the most widely used fibrinolytic in STEMI.

Early administration is paramount as clinical benefits lessen with increasing time from symptom onset. Target time for administration in emergency medical services (EMS) systems of care should include the potential for prehospital thrombolysis, which has been shown to decrease mortality by 17% in meta-analysis., compared to delay and in hospital administration. As a compared to delay and in hospital administration.

In complex uncertain cases, including issues around delayed presentation, discussion with local cardiac experts on optimal management may include deferral of thrombolysis and transfer to cardiac centre for PCI.

There are several contraindications to fibrinolysis that healthcare practitioners need to be aware of:

2.4.1 Absolute contraindications

- Haemorrhagic stroke or stroke of unknown origin at any time
- Ischaemic stroke in the preceding 6 months
- Central nervous system damage, neoplasms, or arteriovenous malformation
- Recent major trauma/surgery/head injury (within the preceding month)
- Gastro-intestinal bleeding within the last month
- Known bleeding disorder (excluding menses)
- Aortic dissection
- Non-compressible punctures within the past 24 hours (e.g. lumbar puncture, liver biopsy).

2.4.2 Relative contraindications

- Transient ischaemic attack in preceding 6 months
- Oral anticoagulant therapy
- Pregnancy or within 1-week post-partum
- Prolonged or Traumatic resuscitation
- Refractory hypertension (systolic blood pressure >180mmHg and/or diastolic blood pressure >110mmHg)
- Advanced liver disease
- Infective endocarditis
- Active peptic ulcer.

2.5 | Transfer post thrombolysis (Pharmaco-invasive strategies)

2.5.1 Rescue PCI

Urgent angiography and rescue PCI is indicated if fibrinolysis is unsuccessful (defined as persistent ST-segment elevation > 50% at 60 to 90 minutes) or if there are worsening symptoms or hemodynamic or electrical instability.²⁶ Re-administration of fibrinolysis is not effective and therefore not recommended.²⁶

2.5.2 Routine early angiography strategy after successful thrombolysis

Patients with successful fibrinolysis who are not treated at a PCI capable centre should be routinely transferred for angiography and PCI performed within 2 to 24 hours after fibrinolysis. Multiple studies including meta-analyses have demonstrated early angiography within 24 hours reduces recurrent ischemia and reinfarction [CoSTR 2015, weak recommendation, very-low-quality evidence].²⁷

2.6 | Cardiac Arrest/Shock Centres

A cardiac arrest/shock centre is a hospital that has the facilities to provide a comprehensive package of post resuscitation care including PCI and targeted temperature management in the intensive care unit (ICU). There is evidence from observational studies that such centres have better initial survival and better neurologically intact survival.¹³ The evidence supporting triaging to such centres is however weak with an absence of randomised studies supporting such a strategy.¹⁴ It is reasonable for each local network to consider transporting patients with OHCA or cardiogenic shock directly to a more specialised cardiac arrest/shock centre (Refer to ANZCOR Guideline 11.7).

2.7 | PCI in NSTEMI

In patients with non-ST elevation myocardial infarction (NSTEMI), an early invasive strategy (<24h) of coronary angiography and PCI is recommended in patients with high-risk features (including a confirmed diagnosis of NSTEMI, dynamic ST-T segment changes suggestive of ischemia, transient ST elevation, or GRACE score >140).²⁸

Urgent angiography should be considered among patients with refractory chest pain despite medications; haemodynamic instability or evidence of hypoperfusion; life-threatening arrhythmia; heart failure clearly due to NSTEMI; or in patients with high-risk ECG changes.²⁸

Abbreviations

Abbreviation	Meaning/Phrase
ACS	Acute coronary syndrome
ANZCOR	Australian and New Zealand Committee on Resuscitation
ARC	Australian Resuscitation Council
CoSTR	Consensus on Science with Treatment Recommendations
ECG	Electrocardiograph
ЕСМО	Extracorporeal membrane oxygenation
ED	Emergency department
EMS	Emergency medical services
ICH	Intracranial haemorrhage
ICU	Intensive care unit
NSTEMI	Non-ST elevation myocardial infarction
ОНСА	Out of hospital cardiac arrest
PCI	Percutaneous coronary intervention

PPCI	Primary percutaneous coronary intervention
ROSC	Return of spontaneous circulation
STEMI	ST elevation myocardial infarction

About this Guideline

Search date/s	This review was completed in October 2023
Questions/PICOs:	This guideline has been developed from the previous ANZCOR guideline 2016 and questions included in the ILCOR 2015 and 2022 CoSTR
Method:	Literature review of the most recent acute coronary syndrome and related guidelines from the Australian Heart Foundation / Cardiac Society of Australia and NZ (2016), the European Society of Cardiology (2020) in addition to related ILCOR reviews to produce a locally relevant document.
Main Changes:	
Principal reviewers:	Dion Stub, Peter Leman, Tony Scott, George Lukas, Luke Dawson
Other consultation:	N/A
Worksheet:	N/A
Approved:	December 2024
Guideline superseded:	Guidelines 14.0, 14.1, 14.1.2, 14.2, 14.3

- 1. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 esc guidelines for the management of acute myocardial infarction in patients presenting with st-segment elevation: The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the european society of cardiology (esc). *Eur Heart J.* 2018;39:119-177
- 2. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. *N Engl J Med*. 2003;349:733-742
- 3. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The primary angioplasty in myocardial infarction study group. *N Engl J Med*. 1993;328:673-679
- 4. Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016. *Med J Aust*. 2016;205:128-133
- 5. Bradley EH, Herrin J, Elbel B, McNamara RL, Magid DJ, Nallamothu BK, et al. Hospital quality for acute myocardial infarction: Correlation among process measures and relationship with short-term mortality. *Jama*. 2006;296:72-78
- 6. Bradley EH, Herrin J, Wang Y, McNamara RL, Radford MJ, Magid DJ, et al. Door-to-drug and door-to-balloon times: Where can we improve? Time to reperfusion therapy in patients with st-segment elevation myocardial infarction (STEMI). *Am Heart J*. 2006;151:1281-1287
- 7. McNamara RL, Wang Y, Herrin J, Curtis JP, Bradley EH, Magid DJ, et al. Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. *J Am Coll Cardiol*. 2006;47:2180-2186
- 8. Nallamothu BK, Wang Y, Magid DJ, McNamara RL, Herrin J, Bradley EH, et al. Relation between hospital specialization with primary percutaneous coronary intervention and clinical outcomes in ST-segment elevation myocardial infarction: National registry of myocardial infarction-4 analysis. *Circulation*. 2006;113:222-229
- 9. Terkelsen CJ, Sorensen JT, Maeng M, Jensen LO, Tilsted HH, Trautner S, et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. *Jama*. 2010;304:763-771
- 10. Fordyce CB, Al-Khalidi HR, Jollis JG, Roettig ML, Gu J, Bagai A, et al. Association of rapid care process implementation on reperfusion times across multiple ST-segment-elevation myocardial infarction networks. *Circ*. 2017;10:01
- 11. Le May MR, So DY, Dionne R, Glover CA, Froeschl MP, Wells GA, et al. A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. *N Engl J Med*. 2008;358:231-240
- 12. Knot J, Widimsky P, Wijns W, Stenestrand U, Kristensen SD, Van THA, et al. How to set up an effective national primary angioplasty network: Lessons learned from five European countries. *EuroIntervention*. 2009;5:299, 301-309
- 13. Sinning C, Ahrens I, Cariou A, Beygui F, Lamhaut L, Halvorsen S, et al. The cardiac arrest centre for the treatment of sudden cardiac arrest due to presumed cardiac cause aims, function and structure: Position paper of the Association for acute cardiovascular care of the European Society of Cardiology (AVCV), European Association of percutaneous coronary interventions (EAPCI), European Heart Rhythm Association (EHRA), European Resuscitation Council (ERC), European Society for Emergency Medicine (EUSEM) and European Society of Intensive Care Medicine (ESICM). Europ Heart J Acute Cardiovasc Care. 2020;9:S193-S202

- 14. Yeung J, Matsuyama T, Bray J, Reynolds J, Skrifvars MB. Does care at a cardiac arrest centre improve outcome after out-of-hospital cardiac arrest? a systematic review. *Resuscitation*. 2019;137:102-115
- 15. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. *Lancet*. 2003;361:13-20
- 16. Nikolaou NI, Welsford M, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H, et al. Part 5: Acute coronary syndromes: 2015 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. *Resuscitation*. 2015;95:e121-146
- 17. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: Is timing (almost) everything? *Am J Cardiol*. 2003;92:824-826
- 18. Betriu A, Masotti M. Comparison of mortality rates in acute myocardial infarction treated by percutaneous coronary intervention versus fibrinolysis. *Am J Cardiol*. 2005;95:100-101
- 19. Boersma E, Primary Coronary Angioplasty vs. Thrombolysis G. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. *Eur Heart J.* 2006;27:779-788
- 20. Kern KB, Radsel P, Jentzer JC, Seder DB, Lee KS, Lotun K, et al. Randomized pilot clinical trial of early coronary angiography versus no early coronary angiography after cardiac arrest without ST-segment elevation: The pearl study. *Circulation*. 2020;142:2002-2012
- 21. Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen M, et al. Coronary angiography after cardiac arrest without ST-segment elevation. *N Engl J Med*. 2019;380:1397-1407
- 22. Pinto DS, Frederick PD, Chakrabarti AK, Kirtane AJ, Ullman E, Dejam A, et al. Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. *Circulation*. 2011;124:2512-2521
- 23. Bjorklund E, Stenestrand U, Lindback J, Svensson L, Wallentin L, Lindahl B. Pre-hospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance-transported real-life patients with ST-elevation myocardial infarction. *Eur Heart J.* 2006;27:1146-1152
- 24. Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. *Jama*. 2000;283:2686-2692
- 25. Welsh RC, Travers A, Senaratne M, Williams R, Armstrong PW. Feasibility and applicability of paramedic-based prehospital fibrinolysis in a large North American center. *Am Heart J*. 2006;152:1007-1014
- 26. Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. *N Engl J Med*. 2013;368:1379-1387
- 27. Borgia F, Goodman SG, Halvorsen S, Cantor WJ, Piscione F, Le May MR, et al. Early routine percutaneous coronary intervention after fibrinolysis vs. Standard therapy in st-segment elevation myocardial infarction: A meta-analysis. *Eur Heart J.* 2010;31:2156-2169
- 28. Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. EHJ Volume 42, Issue 14, 7 April 2021, Pages 1289-1367

Referencing this guideline

When citing the ANZCOR Guidelines we recommend:

ANZCOR, 2025, Guideline 14.3 - Acute Coronary Syndromes: Reperfusion Strategy, accessed 3 April 2025,

https://www.anzcor.org/home/acute-coronary-syndromes/guideline-14-3-acute-coronary-syndromes-reperfusion-strategy/